Product
Lenvatinib+Toripalimab.
1 clinical trial
1 indication
Indication
Recurrent Ovarian CarcinomaClinical trial
A Prospective Phase II Clinical Trial of Lenvatinib in Combination With Toripalimab for Patients With Platinum-Resistant Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-12-31